A Study With Imlifidase in Anti-GBM Disease
← catalyst calendarSponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
50actual
Sites
48
Countries
Austria, Belgium, Czechia +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company decision, not due to any safety reason.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-02 | actual | The whole study's end, after follow-up |
| First posted | 2023-01-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Anti-Glomerular Basement Membrane Disease
- Anti-Glomerular Basement Membrane Antibody Disease
- Goodpasture Syndrome
- Good Pasture Syndrome
Interventions
- Drug: Imlifidase — also filed as IdeS, HMED-IdeS
- Procedure: Plasma exchange (PLEX) — also filed as PE
- Drug: Cyclophosphamide (CYC)
- Drug: Glucocorticoids
Primary outcome
what the primary-completion date above is the date OFRenal function as evaluated by estimated glomerular filtration rate (eGFR) at 6 months
measured At 6 months after randomisation
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed